Or­chard lines up mon­ey for pro­posed Lib­meldy ex­pan­sion; Har­bour touts PhI­II

Gene ther­a­py mak­er Or­chard Ther­a­peu­tics is ex­tend­ing its cash run­way in­to 2025 with new fi­nanc­ing agree­ments to bankroll its path to reg­u­la­to­ry ap­proval.

The Lon­don and Boston biotech said it could gar­ner $188 mil­lion via a se­cu­ri­ties pur­chase agree­ment and a pri­vate place­ment of war­rants. Back­ers in­clude RA Cap­i­tal, Deep Track Cap­i­tal, Cowen Health­care, Wood­line Part­ners and Zen­tree In­vest­ments.

Or­chard eyes US clear­ance of OTL-200, a gene ther­a­py can­di­date for metachro­mat­ic leukody­s­tro­phy, af­ter cut­ting back on oth­er pro­grams last year. The treat­ment is ap­proved in the EU and oth­er Eu­ro­pean re­gions as Lib­meldy and brought in $18.8 mil­lion last year, Or­chard said Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER